Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
VRNA Stock Price: Over 15% Increase Pre-Market Explanation
08:38am, Thursday, 10'th Jun 2021
The stock price of Verona Pharma PLC (NASDAQ: VRNA) increased by over 15% pre-market. This is why it happened.
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
02:00am, Tuesday, 25'th May 2021
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces
Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its pot
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
07:17am, Saturday, 01'st May 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
02:00am, Thursday, 29'th Apr 2021
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
02:00am, Friday, 23'rd Apr 2021
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Wednesday, 21'st Apr 2021
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Revisiting Verona Pharmaceuticals
01:52pm, Sunday, 28'th Feb 2021
Today, we take our first new look at Verona Pharmaceuticals in just over a year. The company has advanced its pipeline since then and is well-funded over the near term.
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
08:44pm, Friday, 26'th Feb 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
05:11am, Tuesday, 02'nd Feb 2021
Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstruct
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
02:00am, Monday, 23'rd Nov 2020
Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
02:00am, Monday, 09'th Nov 2020
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
09:25am, Sunday, 01'st Nov 2020
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
03:00am, Thursday, 29'th Oct 2020
Initiated ENHANCE Phase 3 clinical trials in COPD
Verona Pharma plc : Update on AIM Delisting
07:01am, Wednesday, 28'th Oct 2020
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intend
